ReviewFrontiers in chemistry2026
Trypanosomatid parasites, translational research in a One Health, One World environment.
Review in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adequate policies to achieve universal access to high-quality diagnostics and therapeutics in the challenge represented by Trypanosomatidae-borne diseases remain essential to command surveillance as a successful tool and a way to delay the unavoidable surge of resistance toward the currently used drugs. In the case of leishmaniasis, even for uncomplicated cutaneous leishmaniasis, most patients in endemic regions are treated with systemic therapies due to reasons such as local protocol misalignment, limited access to new technologies, and lesions being located in anatomical areas other than the face or near the joints. These facts constitute a challenge for rural patients, especially in endemic areas, with limited access to medical facilities and compromising treatment adherence and clinical follow-up, thus increasing the evolution of treatment failure. In pharmacological-pharmaceutical terms, this means that there is an urgent need to minimize the rate of drug attrition and maximize the potential for success. For example,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.